Biology:mRNA-5671
From HandWiki
Short description: Cancer vaccine candidate
| Vaccine description | |
|---|---|
| Target disease | Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene |
| Type | mRNA |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code | |
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]
References
- ↑ "mRNA 5671". Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800051102.
- ↑ "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mrna-derived-kras-targeted-vaccine-v941.
- ↑ Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov
 |  |
